There are currently 621 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: UC Davis Medical Center, Sacramento, California +1 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
NCT04844359
Recruiting
Up to 135 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/19/2024
Locations: University of California Davis, Sacramento, California
Conditions: Hypersensitivity Pneumonitis
Register for Updates
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT04496739
Recruiting
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers. Decision support tools are designed to improve informed choice about breast cancer chemoprevention. Recognizing barriers and facilitators that can influence the adoption of decision support tools at recruitment centers may help researchers learn how to best implement them into clinical practice.
Gender:
All
Ages:
All
Trial Updated:
03/18/2024
Locations: Kaiser Permanente Downtown Commons, Sacramento, California +1 locations
Conditions: Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
Register for Updates
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Recruiting
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: Venetoclax and azacitidine (investigational combination) Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of California - Davis, Sacramento, California
Conditions: Acute Myeloid Leukemia
Register for Updates
Candin for the Treatment of Common Warts
NCT05889845
Recruiting
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: does treatment with Candin result in better clearance of warts than placebo how many injections are required to result in wart clearance Participants will have one wart selected for injection every two weeks until clearance return 12 weeks aft... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/15/2024
Locations: Integrative Skin Research, Sacramento, California
Conditions: Common Warts (Verruca Vulgaris)
Register for Updates
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577
Recruiting
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall... Read More
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Sacramento, California
Conditions: Prostate Cancer
Register for Updates
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344
Recruiting
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: GSK Investigational Site, Sacramento, California
Conditions: Nonalcoholic Fatty Liver Disease
Register for Updates
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
NCT03031730
Recruiting
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)
NCT05275686
Recruiting
Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2024
Locations: Sacramento Ear, Nose & Throat, Sacramento, California
Conditions: Eustachian Tube Dysfunction
Register for Updates
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
NCT05893537
Recruiting
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/12/2024
Locations: Retinal Consultants Medical Group, Sacramento, California
Conditions: Age-Related Macular Degeneration
Register for Updates
XTX301 in Patients With Advanced Solid Tumors
NCT05684965
Recruiting
This is a first-in-human, multicenter, Phase 1, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: University of California, Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Solid Tumor
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Sacramento, California +1 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates